Cognition Therapeutics Inc (CGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $64.65M
Last updated: Nov 17, 2026 at 11:03 AM ET
Cognition Therapeutics Inc (CGTX) Stock Forecast
Analysts expect Cognition Therapeutics (CGTX) to earn -$0.19 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus is unchanged.
- Fiscal year ending Dec 31, 2026
- -$0.19
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.19
- EPS consensus
- Next report
- Mar 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.19 | -$0.19 to -$0.18 | 2 |
| Dec 31, 2027 | -$0.19 | -$0.19 to -$0.18 | 2 |
Quarterly Estimates
The EPS consensus rises from -$0.14 for the quarter ending Dec 31, 2026 to -$0.04 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.25 to -$0.05 | 5 |
| Mar 31, 2027 | -$0.04 | -$0.04 to -$0.04 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.35.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.19 | -$0.30 | -$0.30 | -$0.30 | -$0.35 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.19 | -$0.22 | -$0.22 | -$0.22 | -$0.22 | N/A |
| Quarter ending Mar 31, 2027 | -$0.04 | -$0.05 | -$0.05 | -$0.05 | -$0.05 | N/A |
Frequently Asked Questions About CGTX
What is the CGTX stock forecast?
Consensus analyst estimates put Cognition Therapeutics's EPS at -$0.19 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Buy.
How do analysts rate CGTX stock?
Of 3 analysts covering Cognition Therapeutics, 0 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CGTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.19, with estimates from -$0.19 to -$0.18 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.19, with estimates from -$0.19 to -$0.18 from 2 analysts.
How many analysts cover CGTX?
3 analysts rate Cognition Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CGTX pages: Overview, Earnings, Forecast, Financials, Competitors